Curis, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own0.10% Shs Outstand91.64M Perf Week-6.92%
Market Cap66.93M Forward P/E- EPS next Y-0.73 Insider Trans-5.65% Shs Float85.92M Perf Month-29.31%
Income-51.60M PEG- EPS next Q-0.17 Inst Own73.40% Short Float6.15% Perf Quarter-77.03%
Sales10.50M P/S6.37 EPS this Y19.30% Inst Trans-9.10% Short Ratio2.19 Perf Half Y-85.64%
Book/sh0.83 P/B0.88 EPS next Y-10.60% ROA-31.50% Target Price11.80 Perf Year-94.73%
Cash/sh1.31 P/C0.55 EPS next 5Y- ROE-54.00% 52W Range0.70 - 15.60 Perf YTD-84.70%
Dividend- P/FCF- EPS past 5Y26.30% ROI-45.40% 52W High-95.33% Beta3.16
Dividend %- Quick Ratio13.00 Sales past 5Y7.20% Gross Margin95.20% 52W Low3.87% ATR0.09
Employees60 Current Ratio13.00 Sales Q/Q-4.50% Oper. Margin- RSI (14)28.93 Volatility8.86% 10.69%
OptionableYes Debt/Eq0.00 EPS Q/Q-62.00% Profit Margin- Rel Volume0.46 Prev Close0.71
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume2.41M Price0.73
Recom2.20 SMA20-18.50% SMA50-51.08% SMA200-84.14% Volume1,102,358 Change3.03%
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jan-22-15Reiterated Oppenheimer Outperform $3 → $5
Jan-21-15Reiterated ROTH Capital Buy $10 → $6
May-09-14Reiterated Oppenheimer Outperform $4.50 → $3
Oct-02-13Initiated Robert W. Baird Outperform $7
Sep-30-13Initiated Chardan Capital Markets Buy $6
Nov-14-12Initiated Stifel Nicolaus Hold
Jan-31-12Reiterated Summer Street Research Buy $5 → $7
Jan-31-12Reiterated Brean Murray Buy $5 → $6
Dec-09-11Initiated Oppenheimer Outperform $6
Oct-06-11Initiated Summer Street Research Buy $5
Sep-22-11Initiated MLV Capital Buy $8.50
May-12-22 10:26AM  
May-11-22 08:59AM  
May-06-22 01:01AM  
May-05-22 06:05PM  
May-04-22 09:35AM  
Apr-28-22 04:00PM  
Apr-21-22 07:28AM  
Apr-12-22 11:57AM  
Apr-11-22 08:00AM  
Apr-07-22 04:01PM  
Apr-05-22 08:00AM  
Apr-04-22 08:53AM  
Mar-07-22 11:03AM  
Mar-04-22 04:40AM  
Feb-25-22 07:30AM  
Feb-24-22 05:40PM  
Feb-17-22 04:00PM  
Jan-31-22 05:38PM  
Jan-20-22 08:00AM  
Jan-14-22 11:33AM  
Jan-07-22 04:01PM  
Jan-06-22 07:00AM  
Jan-03-22 08:00AM  
Dec-22-21 09:41AM  
Dec-15-21 08:00AM  
Dec-14-21 12:00PM  
Dec-06-21 08:00AM  
Nov-29-21 08:54AM  
Nov-24-21 10:00AM  
Nov-16-21 10:00AM  
Nov-10-21 04:32AM  
Nov-09-21 05:45PM  
Nov-08-21 08:00AM  
Nov-04-21 11:11AM  
Nov-02-21 04:01PM  
Oct-25-21 11:37AM  
Oct-17-21 08:35PM  
Oct-07-21 09:00AM  
Oct-06-21 04:01PM  
Sep-20-21 11:50AM  
Sep-08-21 10:15AM  
Sep-02-21 08:00AM  
Aug-06-21 02:27AM  
Aug-04-21 09:01AM  
Aug-03-21 05:25PM  
Jul-27-21 04:01PM  
Jul-07-21 04:01PM  
Jul-06-21 12:52PM  
Jun-28-21 05:17PM  
Jun-26-21 05:50PM  
Jun-25-21 08:00AM  
Jun-22-21 06:35PM  
Jun-21-21 05:37PM  
Jun-20-21 01:53PM  
Jun-17-21 06:42PM  
Jun-16-21 04:50AM  
Jun-14-21 03:26AM  
Jun-11-21 05:54PM  
Jun-08-21 03:16PM  
Jun-04-21 08:00AM  
Jun-01-21 08:00AM  
May-25-21 08:01AM  
May-20-21 09:05AM  
May-13-21 06:42PM  
May-12-21 04:01PM  
May-05-21 08:00AM  
May-04-21 03:00PM  
Apr-19-21 08:00AM  
Apr-07-21 04:01PM  
Apr-06-21 08:00AM  
Mar-25-21 10:17AM  
Mar-19-21 01:42AM  
Mar-17-21 09:05AM  
Mar-16-21 09:00PM  
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dentzer James EPresident & CEOJan 31Sale3.073,0949,49964,877Jan 31 05:14 PM
Dentzer James EPresident & CEOJan 27Sale3.182,4067,65167,971Jan 31 05:14 PM